AR032601A1 - UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO - Google Patents
UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTOInfo
- Publication number
- AR032601A1 AR032601A1 ARP000105238A ARP000105238A AR032601A1 AR 032601 A1 AR032601 A1 AR 032601A1 AR P000105238 A ARP000105238 A AR P000105238A AR P000105238 A ARP000105238 A AR P000105238A AR 032601 A1 AR032601 A1 AR 032601A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- alkyl
- hydrogen
- quinolin
- derived
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 abstract 2
- BXAIQPPVOCFPQA-UHFFFAOYSA-N 1-aminopyrrolidin-3-ol Chemical group NN1CCC(O)C1 BXAIQPPVOCFPQA-UHFFFAOYSA-N 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000007996 neuronal plasticity Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto derivado de quinolin-4-il de la formula general (1) en donde: R1 es hidrogeno, alquilo C1-4, alcoxilo C1-4, hidroxilo, amino, nitro, ciano, alquilo C1-4 amino, di-alquil-amino C1-4 o halogeno; R2 es hidrogeno, alquilo C1-4, amino, pirrolidin-3-ol. pirrolidin-2-il-metanol o -NHCH2CHROH; R3 es hidrogeno o halogeno; R es hidrogeno, alquilo C1-4 o -CH2OH; n es 1 o 2, y a sus sales de adicion de ácido farmacéuticamente aceptables. El compuesto es un bloqueador selectivo de subtipo receptor del NMDA (N-metil-D-aspartato), que tienen funcion clave en modular actividad y plasticidad neuronal en procesos de induccion que son fundamentales en el desarrollo de CNS, así como aprendimiento y formacion de la memoria. También se divulga un medicamento que contiene uno o más del compuesto derivado de quinolin-4-il, un procedimiento para la preparacion del compuesto y el uso del compuesto para el tratamiento de enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99120131 | 1999-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032601A1 true AR032601A1 (es) | 2003-11-19 |
Family
ID=8239160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105238A AR032601A1 (es) | 1999-10-08 | 2000-10-05 | UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6339093B1 (es) |
| EP (1) | EP1090917B1 (es) |
| JP (1) | JP3385318B2 (es) |
| KR (1) | KR100398562B1 (es) |
| CN (1) | CN1162424C (es) |
| AR (1) | AR032601A1 (es) |
| AT (1) | ATE313538T1 (es) |
| AU (1) | AU777881B2 (es) |
| BR (1) | BR0004709A (es) |
| CA (1) | CA2322309C (es) |
| DE (1) | DE60024947T2 (es) |
| DK (1) | DK1090917T3 (es) |
| EG (1) | EG23872A (es) |
| ES (1) | ES2254095T3 (es) |
| HR (1) | HRP20000652A2 (es) |
| HU (1) | HUP0003938A2 (es) |
| ID (1) | ID27526A (es) |
| IL (1) | IL138916A0 (es) |
| MA (1) | MA26753A1 (es) |
| MX (1) | MXPA00009771A (es) |
| NO (1) | NO20005031L (es) |
| NZ (1) | NZ507303A (es) |
| PE (1) | PE20010660A1 (es) |
| PL (1) | PL343057A1 (es) |
| TR (1) | TR200002893A2 (es) |
| ZA (1) | ZA200005447B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| WO2002072542A2 (en) | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
| US6831087B2 (en) * | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| JP5543917B2 (ja) * | 2007-06-18 | 2014-07-09 | リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ | スルホニル−キノリン誘導体 |
| CN101815518B (zh) | 2007-06-29 | 2013-01-09 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| AU2008304231A1 (en) * | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| RS60834B1 (sr) | 2015-12-09 | 2020-10-30 | Cadent Therapeutics Inc | Modulatori heteroaromatskog nmda receptora i njihove upotrebe |
| ES2849560T3 (es) * | 2016-05-04 | 2021-08-19 | Genoscience Pharma Sas | Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| CR20210125A (es) | 2018-08-03 | 2021-06-30 | Cadent Therapeutics Inc | Moduladores del receptor nmda heteroaromático y usos de los mismos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8409745D0 (en) * | 1984-04-14 | 1984-05-23 | Beecham Group Plc | Active compounds |
| US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
| GB8716972D0 (en) * | 1987-07-17 | 1987-08-26 | Pfizer Ltd | Treatment of cardiac arrhythmias |
| JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
| US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
| US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
| GB9203798D0 (en) * | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| GB9305644D0 (en) * | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| US5567718A (en) * | 1994-08-11 | 1996-10-22 | Hoechst Marion Roussel Inc. | 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
-
2000
- 2000-09-26 US US09/669,648 patent/US6339093B1/en not_active Expired - Fee Related
- 2000-09-29 CN CNB001290843A patent/CN1162424C/zh not_active Expired - Fee Related
- 2000-10-02 ES ES00121561T patent/ES2254095T3/es not_active Expired - Lifetime
- 2000-10-02 AT AT00121561T patent/ATE313538T1/de not_active IP Right Cessation
- 2000-10-02 EP EP00121561A patent/EP1090917B1/en not_active Expired - Lifetime
- 2000-10-02 DE DE60024947T patent/DE60024947T2/de not_active Expired - Lifetime
- 2000-10-02 DK DK00121561T patent/DK1090917T3/da active
- 2000-10-03 HR HR20000652A patent/HRP20000652A2/hr not_active Application Discontinuation
- 2000-10-03 PE PE2000001045A patent/PE20010660A1/es not_active Application Discontinuation
- 2000-10-03 NZ NZ507303A patent/NZ507303A/xx unknown
- 2000-10-04 JP JP2000304354A patent/JP3385318B2/ja not_active Expired - Fee Related
- 2000-10-04 ID IDP20000858D patent/ID27526A/id unknown
- 2000-10-04 CA CA002322309A patent/CA2322309C/en not_active Expired - Fee Related
- 2000-10-04 EG EG20001265A patent/EG23872A/xx active
- 2000-10-04 MA MA26080A patent/MA26753A1/fr unknown
- 2000-10-04 TR TR2000/02893A patent/TR200002893A2/xx unknown
- 2000-10-05 ZA ZA200005447A patent/ZA200005447B/xx unknown
- 2000-10-05 AR ARP000105238A patent/AR032601A1/es not_active Application Discontinuation
- 2000-10-05 MX MXPA00009771A patent/MXPA00009771A/es active IP Right Grant
- 2000-10-05 IL IL13891600A patent/IL138916A0/xx unknown
- 2000-10-06 HU HU0003938A patent/HUP0003938A2/hu unknown
- 2000-10-06 BR BR0004709-0A patent/BR0004709A/pt not_active Application Discontinuation
- 2000-10-06 AU AU64100/00A patent/AU777881B2/en not_active Ceased
- 2000-10-06 NO NO20005031A patent/NO20005031L/no not_active Application Discontinuation
- 2000-10-07 KR KR10-2000-0059049A patent/KR100398562B1/ko not_active Expired - Fee Related
- 2000-10-09 PL PL00343057A patent/PL343057A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9904505D0 (sv) | Novel compounds | |
| BR0016543A (pt) | Novos derivados de piperidina e piperazina | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| AR032601A1 (es) | UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO | |
| CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
| TR200102042T2 (tr) | Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri. | |
| AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
| TW200621762A (en) | Novel compounds | |
| NO960630L (no) | Heterocykler anvendelige som neurokinin antagonister | |
| UY27592A1 (es) | Nuevo uso | |
| TR200000520A2 (tr) | 4-Fenil-piridin türevleri. | |
| AU2003301020A1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| TR200302214T4 (tr) | Psoriasis tedavisi için kullanilan pteridine bileşkenleri | |
| SE9903760D0 (sv) | New compounds | |
| AR035422A1 (es) | Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos. | |
| MXPA04005209A (es) | Antagonistas del receptor de adenosina a2a. | |
| NO20020282D0 (no) | Nytt difenylpiperidinderivat | |
| ATE300541T1 (de) | Pyrazolopyridinderivate | |
| BRPI0519398A2 (pt) | compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina | |
| UY27474A1 (es) | Formulación de dosificación oral de fusion instantanea. | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| AR027578A1 (es) | Derivados de indano | |
| ATE384708T1 (de) | Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren | |
| WO2001010860A3 (en) | Quinazolinone and azaquinazolinone derivatives | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |